The Board of Directors of PI Industries Limited met on February 12, 2026, to approve the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. Key outcomes include the declaration of an interim dividend of ₹5.00 per share (500%), payable by March 13, 2026. The results show strong performance across both standalone and consolidated segments in the Agrochemicals business.
Board Meeting Highlights: February 12, 2026
PI Industries Limited announced the outcomes of its Board meeting held today, February 12, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ending December 31, 2025, along with the Limited Review Reports from the Statutory Auditors.
Interim Dividend Declaration
The Board has declared an interim dividend of ₹5.00 (Rupees five only) per equity share, representing 500% on the face value of Re. 1/- each. The payment date for eligible members is set for on or before Friday, March 13, 2026. Consequently, the record date for determining eligible members has been fixed as Monday, February 23, 2026.
Standalone Financial Performance (Q3 FY2025-26 vs Q3 FY2024-25)
For the quarter ended December 31, 2025, the Standalone Profit After Tax stood at ₹2,816 Million, compared to ₹4,238 Million in the corresponding period last year (Q3 FY2024-25). Total Income for the quarter was ₹13,459 Million. For the nine months ended December 31, 2025, the Profit After Tax was ₹12,370 Million.
Consolidated Financial Performance (Q3 FY2025-26 vs Q3 FY2024-25)
On a consolidated basis, the Profit After Tax for the quarter ended December 31, 2025, was ₹3,113 Million, against ₹3,727 Million reported in Q3 FY2024-25. Total Consolidated Income reached ₹14,424 Million. For the nine months period, the Consolidated Profit After Tax reached ₹11,206 Million. This performance reflected an Exceptional Item gain of ₹1,051 Million, primarily due to the write-back of contingent consideration following a settlement related to the PIHS acquisition.
Exceptional Items and Regulatory Impact
The results reflect an exceptional item gain of ₹206 Million in the standalone results and ₹1,051 Million in the consolidated results for the quarter and nine months ending December 31, 2025. This exceptional item is linked to the reassessment of employee benefit obligations following the notification of the New Labour Codes by the Ministry of Labour and Employment, recognized as a non-recurring liability adjustment.
Segmental Performance (Consolidated)
The company operates in two primary segments: Agro Chemicals and Pharma.
- Agro Chemicals: This segment remains the largest contributor, generating Profit Before Tax of ₹14,442 Million for the nine months ended December 31, 2025. Segment Assets stood at ₹1,19,068 Million.
- Pharma: The Pharma segment reported a Profit Before Tax of ₹(999) Million for the nine-month period, alongside Segment Assets of ₹14,012 Million.
The business review process confirmed that the entire QIP funds raised in September 2020 had been utilized by September 30, 2025, primarily directed towards subsidiaries and capital expenditure.
Source: BSE
